Multiple Myeloma Articles | Page 2

BCMA-Directed bb2121 Highly Effective for Myeloma
Treatment with the BCMA-directed CAR T-cell therapy bb2121 induced complete remissions for 56% of patients with relapsed/refractory multiple myeloma. 
Oncology Experts Highlight Practice-Changing Abstracts at ASH 2017
Key opinion leaders share their insight on the pivotal and highly anticipated abstracts across hematologic malignancies, including lymphoma, leukemia, and multiple myeloma, ahead of 2017 ASH Annual Meeting and exactly how these findings could be implemented in and affect clinical practice.
FDA Lifts Holds on 2 Nivolumab Myeloma Trials
The FDA has lifted partial clinical holds placed on the phase I CheckMate-039 and phase II CA204142 trials exploring nivolumab-based regimens in patients with relapsed/refractory multiple myeloma.
Triplet Therapy With Selinexor Tested in Myeloma
Selinexor, a novel drug that targets a tumor-suppressor “cargo” protein mechanism, is being investigated in patients with relapsed/refractory multiple myeloma who have received 1 to 3 prior treatment regimens.
Sameh Mikhail, MD, discusses the promise of daratumumab, as well as the potential of medical marijuana to curb the adverse events seen with potent anticancer drugs.
Novel Agents, Combos Excite in Multiple Myeloma
Dan T. Vogl, MD, highlights the potential with CAR T-cell therapy in the multiple myeloma paradigm.
FDA Approval Sought for Frontline Daratumumab in Myeloma
A supplemental biologics license application has been submitted to the FDA for daratumumab for use in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation.
FDA Grants BCMA CAR T-Cell Therapy Breakthrough Designation in Myeloma
The FDA has granted the the anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy bb2121 a breakthrough therapy designation for previously treated patients with relapsed/refractory multiple myeloma.
Better Outcomes in High-Risk Multiple Myeloma
Because genetic abnormalities play a role in multiple myeloma, it is important to understand these better to improve outcomes, particularly for high-risk patients, said Shaji K. Kumar, MD. 
Optimal Combinations, Sequences Being Explored in Multiple Myeloma
Adam Waxman, MD, discusses emerging regimens for patients with multiple myeloma.
Publication Bottom Border
Border Publication